Opinion|Videos|November 27, 2024
Treatment Goals and First-Line Therapy in PBC
Key Takeaways
- PBC treatment goals include symptom relief, disease progression prevention, and quality of life improvement, adapting to disease severity.
- UDCA, the first-line treatment for PBC, enhances bile flow and reduces liver inflammation, indicated for early-stage patients.
The panel of experts outline the primary treatment goals for patients with primary biliary cholangitis (PBC), detailing how goals adjust based on disease severity, the role of ursodeoxycholic acid (UDCA) as first-line therapy, and the challenges that may require therapy modifications based on biochemical response.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the treatment goals for patients with PBC?
- How do treatment goals change based on the severity of the disease?
- UDCA is recommended as the first-line pharmacological treatment for PBC. How does it work to treat the disease?
- For which patients is it indicated?
- What are some challenges or limitations you encounter when using UDCA that may prompt a need to modify therapy?
- How do you define biochemical response and when?
Advertisement
Related to this article
Sarina Berger Elmariah, MD, PhD, MPH, discusses 3-year nemolizumab data in early responders and what IL-31 blockade means for itch and atopic dermatitis.
Participants described how comorbidities, payer formularies, and patient preference shape biologic choice in asthma and COPD.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, recap the first-ever Breakthrough T1D Clinical and Research Congress.
Alpha-gal syndrome is reaching new regions, but delayed reactions and GI-only symptoms can leave patients undiagnosed for months or years.
Repeated oral steroid bursts are the main trigger for starting a biologic, while therapy for non-type 2 inflammation COPD remains an unmet need.
At Fall Clinical 2026, Aaron S. Farberg, MD, shares how gene expression testing guides melanoma and atopic dermatitis care and what Ameluz PDT adds.
A roundup of updates spanning PsO, atopic dermatitis, alopecia areata, vitiligo, palmoplantar pustulosis, cutaneous sarcoidosis, and discoid lupus.
Catch up on HCPLive’s second-half Fall Clinical 2026 coverage, from HS underdiagnosis in men and long-term acne data to advanced cutaneous SCC care.
Advertisement
Advertisement
Trending on HCPLive
1
Tezepelumab Meets Co-Primary End Points in Phase 3 CROSSING Trial in EoE
2
52-Week Litifilimab Data in Cutaneous Lupus Erythematosus
3
Mirikizumab Shows Early Efficacy in Pediatric UC in SHINE-2 Trial
4
Tenapanor Linked to Lower IBS-C Care Use, With Kyle Staller, MD, MPH
5